Publication Details
Abstract
The study investigates the relationship between insulin resistance and metabolic syndrome and plasma procalcitonin, a biomarker of inflammation. The metabolic syndrome, a collection of disorders that includes dyslipidemia, hypertension, hyperglycemia, and abdominal obesity, raises the risk of type 2 diabetes and cardiovascular illnesses. One of the main elements of metabolic syndrome is insulin resistance. Adipocyte dysfunction and persistent low-grade inflammation may be markers for elevated levels of plasma procalcitonin, which have been linked to higher measures of obesity, metabolic syndrome components, and a higher chance of developing insulin resistance and metabolic syndrome.
Objectives:
To investigate the correlation between plasma Procalcitonin (PCT) and metabolic syndrome components such as abdominal obesity, dyslipidemia, hypertension, hyperglycemia, and insulin resistance, in comparison to healthy individuals.
Result: In this study, 80 healthy participants served as controls, while 120 patients with metabolic syndrome (MetS) were included. Procalcitonin (PCT) levels were found to be considerably higher on average in MetS patients as compared to controls in the study. In particular, the average PCT level for MetS patients was 0.122±0.168 ng/ml, compared to 0.086±0.0047 ng/ml for controls. Given that there was a statistically significant difference between the two groups, PCT may have application as a MetS biomarker.
Subsequent investigation demonstrated a strong relationship between PCT and HOMA-IR-measured insulin resistance. The two had a 0.187 Pearson correlation coefficient, and the p-value was less than 0.05. Furthermore, a number of Metabolic Syndrome components, including BMI, waist circumference, triglycerides, VLDL, hypertension, and fasting blood glucose, were found to significantly correlate with PCT. Nevertheless, no meaningful association between PCT and LDL-C was discovered. Conclusion: The study found that the mean level of procalcitonin (PCT) was significantly higher in patients with metabolic syndrome (MetS) compared to controls.